Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.
Geron Corporation reports recurring developments as a commercial-stage biopharmaceutical company focused on hematologic malignancies. Its first-in-class telomerase inhibitor RYTELO (imetelstat) is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes with transfusion-dependent anemia.
Company updates commonly cover RYTELO net product revenue, U.S. commercialization, financial results and guidance, and continued development of imetelstat in JAK-inhibitor relapsed or refractory myelofibrosis and other hematologic malignancies. Geron news also includes investor conference participation, Nasdaq inducement grants, board appointments, executive leadership changes, and restructuring-related business updates.
Geron (Nasdaq: GERN) granted a stock option to purchase 1,700,000 shares of its common stock to new Chief Business Officer Chinmaya Rath as an inducement to join the company. The option was granted on July 13, 2026 with an exercise price of $1.42 per share, equal to the closing price that day.
The option has a 10-year term and vests over four years: 12.5% after six months from employment start, and the remaining shares in equal monthly installments over the following 42 months, subject to continued service. The grant was approved by the Board’s Compensation Committee under Nasdaq Listing Rule 5635(c)(4) and made pursuant to Geron’s 2018 Inducement Award Plan and related stock option agreement.
Geron (Nasdaq: GERN) announced the appointment of Chinmaya Rath as Chief Business Officer, effective July 13, 2026. According to Geron, Rath will help maximize the value of blood cancer therapy RYTELO globally and support the company’s ambition to build a leading hematology business.
Rath brings over 25 years of U.S. and global biopharma leadership, including senior roles at Novartis, Cellworks, GlycoMimetics, Omega Therapeutics and as Founder CEO of CelluRx. His experience spans major oncology launches, strategy, operations, and venture investing in life sciences.
Geron (Nasdaq: GERN) granted stock options as inducement awards to eight new employees, effective June 17, 2026. The options cover an aggregate 690,000 shares of common stock at an exercise price of $1.23 per share, matching the closing price on the grant date.
The options have a 10-year term and vest over four years: 12.5% on the six-month employment anniversary and the remainder in equal monthly installments over 42 months, subject to continued employment. The awards were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4) and Geron’s 2018 Inducement Award Plan.
Geron (Nasdaq: GERN) announced participation in the Goldman Sachs 47th Annual Global Healthcare Conference. Company management will join a fireside chat on Monday, June 8, 2026 at 8:40 a.m. ET in Miami, Florida.
A live and archived audio webcast will be available via the Investors & Media section of Geron’s website.
Geron (Nasdaq: GERN) granted stock options to five new employees on May 15, 2026, as inducement awards under Nasdaq Listing Rule 5635(c)(4). The options cover an aggregate 333,750 shares at an exercise price of $1.29 per share, with a ten-year term and four-year vesting.
Geron (Nasdaq: GERN) announced the first real-world evidence study of RYTELO (imetelstat) in lower-risk myelodysplastic syndromes (LR-MDS), to be presented at EHA 2026. The Moffitt Cancer Center study in 40 heavily pretreated, transfusion-dependent patients showed 37.5% achieving ≥8-week RBC transfusion independence and a safety profile consistent with prior data.
Geron will also present updated myelofibrosis overall survival analyses and early-phase acute myeloid leukemia and myelofibrosis combination trial data at EHA 2026 and ASCO 2026.
Geron (Nasdaq: GERN) reported Q1 2026 results with RYTELO net product revenue of $51.8M and a reduced net loss of $3.6M ($0.01/share). Cash and marketable securities were $341.0M at March 31, 2026. 2026 guidance reiterated: RYTELO revenue $220M–$240M and total operating expenses $230M–$240M. Key commercial and clinical progress includes demand growth, NCCN chemotherapy order template inclusion, ongoing IMpactMF Phase 3, and leadership additions.
Geron (Nasdaq: GERN) announced management presentations at investor conferences in May 2026. Presentations: Bank of America Healthcare Conference on May 12 at 4:35 p.m. ET in Las Vegas and a Stifel Virtual Targeted Oncology Forum presentation on May 20 at 12:00 p.m. ET. A live and archived audio webcast will be available via the company's Investors and Media website.
Geron (Nasdaq: GERN) will release its first quarter 2026 financial results and business highlights before the market opens on May 6, 2026.
The company will host a conference call and webcast at 8:00 a.m. Eastern Time, with live and archived audio available from the Investors and Media section of its website at www.geron.com.
Geron Corporation (Nasdaq: GERN) reported inducement stock option grants effective April 17, 2026, totaling 855,000 shares to nine newly hired employees.
The options carry a $1.68 exercise price (closing price on the grant date), a 10-year term, and vest over four years with a 12.5% six-month cliff.